P206 ANALYZING ATTRITION POINTS IN INDONESIA'S HYPERTENSION CARE CASCADE: STUDY OF 200,000 POPULATION FROM 2013-2018

Background: According to NCDRisC, Indonesia ranks as the worst performer globally in hypertension control, with control rates of 5.1% for females and 3.6% for males, despite having an income level with better potential outcomes. Hypertension is a leading risk factor for cardiovascular disease (CVD), and its management is critical for reducing major CVD risks. This study aims to identify the significant attrition points in the hypertension care cascade in Indonesia, focusing on identifying where the most significant drop-offs occur at each stage. Methods: The study utilizes data from the 2018 Indonesian Basic Health Research (RISKESDAS), a nationally representative health survey sample of ∼1 million individuals. The hypertension care cascade was divided into stages: prevalence, diagnosis, treatment, and control. Descriptive statistics and attrition analysis were used to analyze the data. Results: Indonesia managed to diagnose 29.6% of its hypertensive population and treat 23.4%, yet only 4.4% achieved control over their condition. Between 2013 and 2018, diagnosis rates slightly decreased from 33.5% to 29.6%, while treatment rates significantly improved, doubling from 10.7% to 23.4%. Control rates modestly improved by ∼60% from 2013 to 2018, from 2.6% to 4.4%. The diagnostic phase showed the highest attrition, with over 70% of the hypertensive population undiagnosed. Improvement in diagnosed-to-treated performance was observed, with conversion rates increasing from 32% in 2013 to 79% in 2018. However, the treatment-to-control conversion remained low at 18%, indicating that 19% of the treated hypertensive population did not achieve control. Huge care gaps are shown in males vs females (Figure 1). Overall, more than 95% of the hypertensive population remains uncontrolled. Conclusion: The most significant drop in the hypertension care cascade occurs at the diagnostic phase, where over 70% of the hypertensive population remains undiagnosed. Despite improvements in treatment rates, the conversion from treatment to control remains low. Addressing the diagnostic gap is critical for enhancing hypertension control and reducing CVD risks in Indonesia.